{
    "name": "sirolimus topical",
    "comment": "Rx",
    "other_names": [
        "Hyftor"
    ],
    "classes": [
        "Dermatologics",
        "mTOR Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/hyftor-sirolimus-topical-4000288",
    "pregnancy": {
        "common": [
            "Based on animal studies and mechanism of action, oral sirolimus can cause fetal harm when administered to pregnant females",
            "Sirolimus topical is systemically absorbed and may result in fetal exposure",
            "Available data from case reports on sirolimus topical use in pregnant females are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Animal reproduction studies have not been conducted with sirolimus topical",
                    "Oral sirolimus 0.5 mg/kg/day caused embryo-fetal lethality in pregnant rats when administered during organogenesis",
                    "Available data do not allow calculation of relevant comparisons between systemic exposure of sirolimus observed in animal studies to systemic exposure that would be expected in humans after topical use"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Based on animal studies with oral sirolimus, may cause fetal harm when administered to pregnant females",
                    "Females of reproductive potential are recommended to avoid becoming pregnant",
                    "Initiate effective contraceptive before starting therapy, during treatment, and for 12 weeks after the final dose "
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on clinical findings and findings in animal studies, male and female fertility may be compromised by sirolimus treatment  ",
                    "Ovarian cysts and menstrual disorders (including amenorrhea and menorrhagia) reported in females with oral sirolimus",
                    "Azoospermia reported in males with oral sirolimus; reversible upon discontinuation of sirolimus in most cases"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available on presence in human milk, effects on breastfed infants, or effects on milk production",
            "After oral administration, sirolimus was present in the milk of lactating rats",
            "Breastfeeding is not recommended during treatment "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to sirolimus or any other component"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Lymphoma and other malignancies, particularly skin, observed after oral sirolimus; instruct patients to minimize or avoid exposure to natural or artificial sunlight, including wearing protective clothing and sunscreen ",
                "Cases of interstitial lung disease (ILD) including pneumonitis, bronchiolitis obliterans organizing pneumonia (BOOP), and pulmonary fibrosis, some fatal, with no identified infectious etiology, reported with oral sirolimus; in some cases, ILD resolved upon discontinuation or dosage reduction; discontinue therapy immediately if symptoms of ILD occur ",
                "Increased serum cholesterol and triglycerides, requiring treatment, observed with oral sirolimus; monitor for hyperlipidemia during treatment",
                "Based on animal studies and mechanism of action, oral sirolimus can cause fetal harm when administered to pregnant females",
                "May impair male fertility"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis have been associated with oral sirolimus",
                        "Elevated sirolimus levels (with or without concomitant ACE inhibitors) may also potentiate angioedema",
                        "Discontinue immediately if hypersensitivity symptoms occur"
                    ]
                },
                {
                    "type": "Serious infections",
                    "description": [
                        "Serious infections, including opportunistic infections, reported after oral sirolimus ",
                        "Progressive multifocal leukoencephalopathy (PML) reports, including cases of fatal PML",
                        "Discontinue immediately if symptoms of infection occur"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Drug interaction studies for sirolimus topical have not been conducted",
                        "Sirolimus is a substrate of CYP3A4 and p-glycoprotine (P-gp)",
                        "Immunizations",
                        "Complete all age-appropriate vaccinations as recommended by current immunization guidelines before initiating",
                        "Avoid use of live vaccines during treatment",
                        "Sirolimus may decrease vaccine efficacy",
                        "CYP3A4 inhibitors",
                        "Monitor for sirolimus adverse effects",
                        "Coadministration of sirolimus with CYP3A4 inhibitors may increase sirolimus systemic exposure",
                        "Drugs that are both substrates and inhibitors of CYP3A",
                        "Monitor",
                        "Systemic exposure of drugs that are both substrates and inhibitors of CYP3A may increase when coadministered with sirolimus"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Dry skin",
            "percent": "28-40"
        },
        {
            "name": "Skin irritation",
            "percent": "31-37"
        },
        {
            "name": "Acne",
            "percent": "7-20"
        },
        {
            "name": "Pruritus",
            "percent": "9-17"
        },
        {
            "name": "Eye irritation",
            "percent": "9"
        },
        {
            "name": "Erythema",
            "percent": "7"
        },
        {
            "name": "Acneiform dermatitis",
            "percent": "3-6"
        },
        {
            "name": "Contact dermatitis",
            "percent": "5"
        },
        {
            "name": "Ocular hyperemia",
            "percent": "3"
        },
        {
            "name": "Skin hemorrhage",
            "percent": "3"
        },
        {
            "name": "Skin irritation",
            "percent": "3"
        },
        {
            "name": "Solar dermatitis",
            "percent": "1"
        },
        {
            "name": "Photosensitivity",
            "percent": "1"
        }
    ]
}